#savethejointTM

 

CINGAL

#savethejointTM


Powerful new treatment for the pain of osteoarthritis

CINGAL® is the first and only approved combination viscosupplement formulated to provide the benefit of a cross-linked Hyaluronic Acid (HA) and a fast acting steroid

The corticosteroid Triamcinolone Hexacetonide (TH) works quickly to reduce inflammation

  • CINGAL delivers a 59% improvement in WOMAC pain at week 1 relative to baseline (p = 0.008)
  • CINGAL delivers a 72% improvement in WOMAC pain at 26 relative to baseline (p = 0.0027)
  • CINGAL delivers an 89% responder rate in the OMERACT-OARSI Responder Index at 1 week
    (p = 0.01671)
  • CINGAL delivers a 92% responder rate in the OMERACT-OARSI Responder Index through
    26 weeks (p = 0.0100)

Lightly crossed-linked HA
CINGAL contains sodium hyaluronate that is lightly cross-linked to increase residence time in the joint

Non-Avian HA
CINGAL is made from ultra pure, high molecular weight sodium hyaluronate produced by bacterial fermentation

No pseudoseptic reactions
No pseudoseptic reactions associated with CINGAL have been reported worldwide

FOR ANY PRODUCT INFORMATION YOU REQUIRE

More information


Company

JOINT OPERATIONS (UK) LLP
Unit 11 Interface Business Park
Bincknoll Lane
Royal Wootton Bassett
Wiltshire
SN4 8SY
UK

Company no. OC396027
VAT no. GB 198327955

Contact

OFFICE HOURS:

Mon - Fri 08:30 to 17:30
Tel. +44 (0) 1793 575 050

OUT OF HOURS BURNS SUPPORT:

Tel. +44 (0)1793 575 041

Joint Operations Helping innovators in their work...

© 2020 Joint Operations Ltd
website development .: Clockwork
Joint Operations is a ISO 9001:2005 registered company
Joint Operations is a ISO 9001:2005 registered company

Helping innovators in their work...

Joint Operations is a ISO 9001:2005 registered company
© 2020 Joint Operations Ltd
website development .: Clockwork